Abstract
Objective: Erythropoiesis stimulating agents (ESAs) are required in most of the patients with end-stage renal disease (ESRD) for treatment of anemia. Subnormal testosterone concentrations are very ...
Highlights
Anemia is present in almost all patients with end-stage renal disease (ESRD).[1]
Erythropoiesis stimulating agents (ESAs) doses decreased by 20% in the testosterone replacement therapy (TRT) group but did not change in the untreated group ( p = 0.03 for comparison between groups)
The ESA doses were lower by *20% in the treated group (Table 1) but did not change in the untreated group ( p = 0.03 for comparison between groups)
Summary
Anemia is present in almost all patients with end-stage renal disease (ESRD).[1] Currently, >90% of ESRD patients are on erythropoiesis stimulating agents (ESAs).[2] Use of ESAs to correct the severe anemia in these patients improves physiological and clinical parameters and quality of life. Targeting higher hemoglobin levels with ESAs results in an increased risk of cardiovascular events.[3] ESAs underwent a label change mandated by FDA in 2011 to reflect that association.[4] These adverse effects may be directly mediated by the hemodynamic or rheological effects of hemoglobin.
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call